Aimmune IPO: Everything You Need to Know

Aimmune IPOAimmune Therapeutics, Inc. (NASDAQ:AIMT) shares are ready to hit the public trading market this week. The pharmaceutical company submitted S-1 filling to the Securities and Exchange Commission (SEC) on July 6, 2015 for its initial public offering (IPO). Here’s what investors need to know about the upcoming Aimmune IPO. (Source: SEC, last accessed August 5, 2015.)

Who is Aimmune?

Aimmune is a research-based company who intends to protect people that suffer from sudden exposures to peanut and other food allergies. The company was founded in 2011 and it is based in Brisbane, California.

What is Aimmune’s Business Model?

According to the data from the Food and Drug Administration (FDA), nearly 30 million people in the U.S. and Europe are believed to have some sort of food allergies, of which peanut is the most dominant.

The company intends to provide a treatment to protect people who are exposed to such life-threatening food allergies. As of now, Aimmune has been able to achieve phase two approval for its peanut allergy treatment, called AR101, from the FDA. With that said, the company, along with its sophisticated research and development department and capital of nearly $60.0 million, plans to develop its allergy treatment products in the foreseeable future.


What is Aimmune’s Capital Expenditure?

The company has managed to increase its research and development expenditure from $3.5 million in 2013 to $8.1 million. This led to the success of achieving the phase two approval from the FDA for its AR101 treatment.

What is Aimmune’s IPO Price?

The company plans to raise as much as $150 million by issuing about eight million shares. The prices are expected to range from $14.00 to $16.00. The primary underwriters for the public offering are Credit Suisse, BofA Merrill Lynch, and Piper Jaffray.

What is Aimmune’s Stock Symbol?

The company asks to be listed on the NASDAQ exchange under the ticker symbol “AIMT.”

How Will Aimmune Use the Money?

The company plans to use the proceeds from its IPO to complete the phase three trial for its latest peanut allergy treatment.